TROV - トロヴァジ―ン (TrovaGene Inc.)

TROVのニュース

   Trovagene Announces Changing of Company Name to Cardiff Oncology and Appointment of Mark Erlander, PhD, as Chief Executive Officer  2020/05/06 12:15:00 PR Newswire
SAN DIEGO, May 6, 2020 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage oncology therapeutics company developing its drug, onvansertib, to treat cancers with the greatest medical need for new treatment options, including KRAS-mutated colorectal cancer, Zytiga®-resistant…
   Trovagene Announces Fourth Quarter and Full-Year 2019 Results  2020/02/27 21:15:00 PR Newswire
SAN DIEGO, Feb. 27, 2020 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage, Precision Cancer Medicine™ oncology therapeutics company developing drugs that target cell division (mitosis) for the treatment of various cancers including prostate, colorectal and leukemia, today…
   Trovagene Receives Approximately $1.45 Million From Exercise of Warrants  2020/01/29 13:00:00 PR Newswire
SAN DIEGO, Jan. 29, 2020 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage, Precision Cancer Medicine™ oncology therapeutics company developing drugs that target cell division (mitosis) for the treatment of various cancers including prostate, colorectal and leukemia,…
   Efficacy, Durability of Response and Safety of Onvansertib Demonstrated in Completed Phase 1b Trial in AML Patients Presented in Oral Session at ASH  2019/12/09 13:00:00 PR Newswire
SAN DIEGO, Dec. 9, 2019 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage, Precision Cancer Medicine™ oncology therapeutics company developing drugs that target cell division (mitosis), for the treatment of various cancers including leukemia, prostate and colorectal, today…
   Trovagene : Announces Data from Acute Myeloid Leukemia (AML) Phase 1b/2 Trial of Onvansertib Chosen for Oral Presentation at ASH 2019 Annual Meeting | MarketScreener  2019/11/06 14:25:49 MarketScreener
SAN DIEGO, Nov. 6, 2019/PRNewswire / -- Trovagene, Inc. , a clinical-stage, Precision Cancer Medicine™ oncology therapeutics company developing drugs that target cell division ,… | November 6, 2019
   Trovagene Announces Changing of Company Name to Cardiff Oncology and Appointment of Mark Erlander, PhD, as Chief Executive Officer  2020/05/06 12:15:00 PR Newswire
SAN DIEGO, May 6, 2020 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage oncology therapeutics company developing its drug, onvansertib, to treat cancers with the greatest medical need for new treatment options, including KRAS-mutated colorectal cancer, Zytiga®-resistant…
   Trovagene Announces Fourth Quarter and Full-Year 2019 Results  2020/02/27 21:15:00 PR Newswire
SAN DIEGO, Feb. 27, 2020 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage, Precision Cancer Medicine™ oncology therapeutics company developing drugs that target cell division (mitosis) for the treatment of various cancers including prostate, colorectal and leukemia, today…
   Trovagene Receives Approximately $1.45 Million From Exercise of Warrants  2020/01/29 13:00:00 PR Newswire
SAN DIEGO, Jan. 29, 2020 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage, Precision Cancer Medicine™ oncology therapeutics company developing drugs that target cell division (mitosis) for the treatment of various cancers including prostate, colorectal and leukemia,…
   Efficacy, Durability of Response and Safety of Onvansertib Demonstrated in Completed Phase 1b Trial in AML Patients Presented in Oral Session at ASH  2019/12/09 13:00:00 PR Newswire
SAN DIEGO, Dec. 9, 2019 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage, Precision Cancer Medicine™ oncology therapeutics company developing drugs that target cell division (mitosis), for the treatment of various cancers including leukemia, prostate and colorectal, today…
   Trovagene : Announces Data from Acute Myeloid Leukemia (AML) Phase 1b/2 Trial of Onvansertib Chosen for Oral Presentation at ASH 2019 Annual Meeting | MarketScreener  2019/11/06 14:25:49 MarketScreener
SAN DIEGO, Nov. 6, 2019/PRNewswire / -- Trovagene, Inc. , a clinical-stage, Precision Cancer Medicine™ oncology therapeutics company developing drugs that target cell division ,… | November 6, 2019

calendar